Atricure announces labeling expansion for cryo nerve block therapy

Mason, ohio--(business wire)--atricure, inc. (nasdaq: atrc), a leading innovator in treatments for atrial fibrillation (afib) and left atrial appendage (laa) management, today announced that it has received u.s. food and drug administration (fda) 510(k) clearance of additional labeling claims for cryo nerve block (cryonb) therapy to include the treatment of adolescent patients (12-21 years of age). the cryoice® and cryosphere™ cryoablation probes are designed to temporarily block pain by ablati
ATRC Ratings Summary
ATRC Quant Ranking